Versant Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Versant Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-558	Closed	-$12K	–	2785
2025 Q4	$12K	Hold	558	–	–	﹤0.01%	1915
2025 Q3	$8.52K	Sell	558 -18	-3%	-$234	﹤0.01%	2004
2025 Q2	$5.1K	Sell	576 -309	-35%	-$2.71K	﹤0.01%	2145
2025 Q1	$6.93K	Buy	+885	New	+$7.41K	﹤0.01%	1902

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Versant Capital Management's AVDL Position: Q1 2026 in Review

Versant Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 558 shares — an estimated $12K sold.

Versant Capital Management first reported a position in AVDL in Q1 2025 and held it in 4 quarters. The position peaked at $12K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Versant Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Versant Capital Management sold 558 Avadel Pharmaceuticals shares in Q1 2026, an estimated $12K.
Versant Capital Management first reported a position in Avadel Pharmaceuticals in Q1 2025 and held it in 4 quarters.
Versant Capital Management's Avadel Pharmaceuticals position peaked at $12K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Versant Capital Management's 13F filing for Q1 2026, filed 7 Apr 2026.